Cytomegalovirus infection: The point in 2001

HIV Medicine

Volumn 2, Issue 4, 2001, Pages 255-259

  Salmon Ceron, D ^a  

^a Cochin Hospital ^*  (France)

Author keywords

AIDS; Cytomegalovirus; Epidemiology; Pre emptive therapy; Prevention; Treatment

Indexed keywords

ANTIRETROVIRUS AGENT; BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; CD4 ANTIGEN; CIDOFOVIR; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR; VIRUS DNA;

CELL COUNT; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DESIGN; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFLAMMATION; NEUTROPENIA; OBSERVATION; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RETINITIS; REVIEW; RISK ASSESSMENT; VIRUS DETECTION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DRUG MONITORING; FOSCARNET; GANCICLOVIR; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; POLYMERASE CHAIN REACTION; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS;

EID: 0035194679     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2001.00082.x     Document Type: Review

References (36)

1. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine
2. Cytomegalovirus viraemia and the CD4 lymphocyte count as predictors of CMV disease in patients with human immunodeficiency virus infection
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Impact of new multidrug therapy containing a protease inhibitor on the occurrence of Mycobacterium avium complex and cytomegalovirus disease in patients with AIDS
5. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy
6. Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease
7. Plasma CMV DNA, pp 65 antigenemia and low CD4 count remain risk factors for CMV disease in patients receiving HAART
8. Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: Incidence and outcome over 2 years
9. Recurrence of CMV disease in patients with a history of CMV retinitis receiving protease inhibitors
10. Characteristics of new episodes and recurrences of CMV disease in HIV infected patients in 1999 (since HAART)
11. Cystoid macular oedema and cytomegalovirus retinitis in patients with HIV disease treated with highly active antiretroviral therapy
12. Immune recovery vitritis associated with inactive cytomegalovirus retinitis
13. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis
14. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS
15. A randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing retinitis in patients with AIDS
16. Oral ganciclovir as maintenance therapy for cytomegalovirus retinitis in patients with AIDS
17. Oral ganciclovir for patients with cytomegalovirus retinitis treated with ganciclovir implant
18. Induction and maintenance therapy for cytomegalovirus central nervous system infection in HIV-infected patients
19. Valganciclovir versus ganciclovir as induction therapy for newly diagnosed cytomegalovirus retinitis: A randomized controlled study
20. In vivo anti-CMV activity and safety of oral 1263W94 in HIV-infected subjects with asymptomatic CMV shedding
21. Comparative evaluation of the cytomegalovirus DNA load in polymorphonuclear leukocytes and plasma of human immunodeficiency virus-infected subjects
22. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk of developing human cytomegalovirus disease
23. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV 1
24. Positive effects of combined antiretroviral therapy on CD+ T cell homeostasis and function in advanced HIV disease
25. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy
26. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients received highly active antiretroviral therapy
27. Discontinuation of anticytomegalovirus therapy in persons with HIV infection and cytomegalovirus retinitis
28. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy
29. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients
30. Discontinuation of maintenance therapy in patients with quiescent cytomegalo-virus retinitis and elevated CD4+ counts
31. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
32. Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have respond to HAART
33. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
34. Restauration immunitaire et prophylaxie des infections opportunisties
35. Recurrent cytomegalovirus (CMV) retinitis in a patient on highly active antiretroviral therapy (HAART) despite apparent immune reconstitution
36. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy